Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases - Kostapanos, Michael S.; Rizos, Christos V.; Elisaf, Moses S. (Drug safety, 2014)
Keywords: Atherosclerosis; Atherosclerosis (general aspects, experimental research); Atherosclerosis - drug therapy; Atherosclerosis - epidemiology; Atherosclerosis - metabolism; Atherosclerosis - prevention & control; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cholesterol; Cholesterol, LDL - metabolism; Diabetes; Disease; Disease prevention; Drug dosages; Drug Safety and Pharmacovigilance; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - etiology; Drug-Related Side Effects and Adverse Reactions - metabolism; Fluorobenzenes - administration & dosage; Fluorobenzenes - adverse effects; Fluorobenzenes - therapeutic use; General and cellular metabolism. Vitamins; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - drug therapy; Hypercholesterolemia - epidemiology; Hypercholesterolemia - metabolism; Medical sciences; Medicine; Medicine & Public Health; Mortality; Pharmacology. Drug treatments; Pharmacology/Toxicology; Population; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Review Article; Risk Assessment; Rosuvastatin Calcium; Statins; Stroke; Studies; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Atorvastatin; Chronic Kidney Disease Patient; Chronic Kidney Disease; Rosuvastatin; Statin; Human; Enzyme; Toxicity; Enzyme inhibitor; Metabolic diseases; Cardiovascular disease; Lipids; Statin derivative; Hypocholesterolemic agent; Vascular disease; Treatment; Benefit risk analysis; HMG-CoA reductase inhibitor; Atherosclerosis; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases; Dyslipemia; Antilipemic agent